How well are patients with atherosclerotic disease treated in general practice? Screening of risk factors and treatment in 1996 and 97; a comparison with the two previous years;Hvor godt behandles pasienter med aterosklerotisk sykdom i allmennpraksis? Risikofaktorer og intervensjon kartlagt i 1996-97 sammenliknet med to år tidligere

Tidsskrift for den Norske Laegeforening

Volumn 118, Issue 15, 1998, Pages 2308-2313

  Svilaas, Arne ^a   Westheim, Arne ^b   Kristoffersen, Jan Emil ^c   Hjartaaker, Jarle ^c   Thoresen, Magne ^d,e  

^a Nymoen Legekontor   (Norway)

^b Hjertemedisinsk Avdeling   (Norway)

^c Skårer Legesenter ^*  (Norway)

^d Medstat Research   (Norway)

^e Seksjon for Medisinsk Statistikk   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; LIPID;

ADULT; AGED; ARTERIOSCLEROSIS; ARTICLE; BLOOD; COMPARATIVE STUDY; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; GENERAL PRACTICE; HUMAN; LIFESTYLE; MALE; MIDDLE AGED; NORWAY; RISK FACTOR; SMOKING;

ADULT; AGED; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CORONARY ARTERIOSCLEROSIS; FAMILY PRACTICE; FEMALE; HUMANS; LIFE STYLE; LIPIDS; MALE; MIDDLE AGED; NORWAY; RISK FACTORS; SMOKING;

EID: 0032503325     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
2. Sacks FM, Pfeffer MA, Move LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after acute myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
3. West of Scotland Coronary Prevention Group. West of Scotland Coronary Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348: 1339-42.
4. Terapianbefaling. Behandling av hyperlipidemi. Nytt fra Statens legemiddelkontroll 1995; 18, nr. 7.
5. Ose L. Behandling av hyperlipidemi. Tidsskr Nor Lægeforen 1995; 115: 3629-31.
6. Svilaas A, Westheim A, Kristoffersen JE, Hjartaaker J. Risikofaktorer og intervensjon ved hjerte- og karsykdommer i allmennpraksis. Tidsskr Nor Lægeforen 1996; 116: 2562-5.
7. Kochar MS. Hypertension in obese patients. Postgrad-Med 1993; 93 (suppl 4): 193-200.
8. Second report of the expert panel on blood cholesterol levels in children and adolescents. National Cholesterol Education Program. NIH Publication no. 93-3095. Washington DC: US Department of Health and Human Services, 1993.
9. International Task Force for Prevention of Coronary Heart Disease. Prevention of coronary heart disease: scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society. Nutr Metab Cardiovasc Dis 1992; 2: 113-156.
10. Erkelens DW. Combination lipid-lowering treatment. Cardiology in General Practice 1996; 4: 1-8.
11. Legemiddelforbruket i Norge 1992-96. Oslo: Norsk Medisinaldepot, 1997: 25-3.
12. Kreisberg RA, Segrest JP. Plasma lipoproteins and coronary artery disease. I: Lewis CE, Oberman A. Epidemiology of lipid disorders in special populations. Boston: Blackwell Scientific Publications, 1992: 3-28.
13. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EURO-ASPIRE Study Group. Eur Heart J 1997; 18: 1569-82.
14. Report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. National Cholesterol Education Program. NIH Publication no. 91-2732. Washington DC: US Department of Health and Human Services, 1991.
15. Kjekshus J. Lipidsenkning - gevinstutenrisiko? Tidsskr Nor Lægeforen 1997; 117: 3184-5.
16. Smith SC jr., Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersch BJ et al. The Secondary Prevention Panel. Preventing heart attack and death in patients with coronary disease. Circulation 1995; 92: 2-4.
17. th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary heart disease events; September 14-15, 1995. J Am Coll Cardiol 1996; 27: 957-1047.
18. Oliver MF, Pyörälä K, Shepherd J. Management of hyperlipidaemia. Why, when and how to treat. Eur Heart J 1997; 18: 371-5.
19. Stone NJ. Priorities in care of the cardiac patient. Cardiology in General Practice 1997; 2: 1-8.
20. Fortmann SP, Marcovina SM. Lipoprotein (a), a clinically elusive lipoprotein particle. Circulation 1997; 95: 295-6.
21. Simons L. Lipoprotein(a) is not associated with coronary heart disease in the elderly: cross-sectional data from the Dubbo study. Atherosclerosis 1993; 99: 87-95.
22. rd Annual Scientific Session. Atlanta, Georgia, March 13-17 1994. J Am Coll Cardiol 1994; 23 (suppl): 131A.
23. Dahlen GH. Felande länken vid hjärt-kärlsjukdom? Läkartidningen 1993; 90: 259-62.
24. Byington RP, Jukema JW, Salonen JT, Pitt B, Busche AV, Hoen H et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995; 92: 2419-25.
25. Erikssen J, Madsen S. Statinbehandling av hyperkolesterolemi. Tidsskr Nor Lægeforen 1997; 117: 3216-9.
26. Retterstol K. Stabilisering av aterosklerotiske plaque: en ny angrepsvinkel for behandling og forebygging av koronarsykdom. Lipidforum 1996; 15: 5-9.
27. Grundy SM. Primary prevention of coronary heart disease: role of cholesterol control in the United States. J Intern Med 1997; 241: 295-306.
28. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-31.
29. Oliver MF, Davies MJ. The atheromatous lipid core. Eur Heart J 1998; 19: 16-8.
30. Pedersen T, Kjekshus J, Pyörälä K, Olsson AG, Cook TJ, Musliner TA et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998; 81: 333-5.
31. Blauw GJ, Lagaay AM, Smelt AHM, West-endorp RGJ. Stroke, statin and cholesterol. A meta-analysis of randomized, placebo-controlled double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997; 28: 946-50.
32. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278: 313-21.
33. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGCoA reductase inhibitors on stroke. A metaanalysis of randomized, controlled trials. Ann Intern Med 1998; 128: 89-95.
34. Kronzon I, Tunick PA. Atheromatous disease of the thoracic aorta: pathologic and clinical implications. Ann Intern Med 1997; 126:629-37.
35. Gillman MW, Cupples A, Millen BE, Ellison RC, Wolf PA. Inverse association of dietary fat with development of ischemic stroke in men. JAMA 1997; 278: 2145-50.
36. Shenvin R, Price TR. Fat chance. Diet and ischemic stroke. JAMA 1997; 278: 2185-6.
37. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease I. JAMA 1988; 260: 2088-93.
38. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147-52.
39. Maseri A. Inflammation, atherosclerosis, and ischemic events - exploring the hidden side of the moon. N Engl J Med 1997; 336: 1014-5.
40. Soumarai SB, Mc Laughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 277: 115-21.
41. Ball SG. Beta-blockers and antithrombotic for secondary prevention after myocardial infarction. Eur Heart J 1998; 19: 14-5.
42. Aymian JZ, Hauptman PJ, Guadagnoli E, Antman EM, Pashos CL, McNeil BJ. Knowledge and practices of generalists and specialist physician regarding drug therapy for acute myocardial infarction. N Engl J Med 1994; 331: 1136-42.
43. Tonstad S. Medikamentell behandling ved hyperlipidemi - ubesvarte spørsmål. Tidsskr Nor Lægeforen 1997; 117: 674-7.
44. Pines A, Levo Y, Ayalaon D. Hormone-replacement therapy compared with simvastatin for postmenopausal women with hypercholesterolemia. N Engl J Med 1998; 338: 63.
45. Aspire Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996; 75: 334-42.
46. Fetters JK, Peterson ED, Shaw LJ, Newby LK, Califf RM. Sex-specific differences in coronary artery disease risk factors, evaluation, and treatment: have they been adequately evaluated? Am Heart J 1996; 131: 796-813.
47. Svilaas A, Bye P, Strom EC, Kolbjørnsen O, Tonstad S, Ose L. Hva skjer med pasienter etter deltakelse i en klinisk Studie? Tidsskr Nor Lægeforen 1997; 117: 4065-9.
48. Pyörälä K, Pedersen T, Kjekshus J, Færgeman O, Olsson AG, Thorgeirsson G. The Scandinavian Simvastatin Survival (4S) Group. Diabetes Care 1997; 20: 614-20.